Study identifier:D1690R00002
ClinicalTrials.gov identifier:NCT02322762
EudraCT identifier:N/A
CTIS identifier:N/A
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
Type 2 Diabetes Mellitus
N/A
No
-
All
15992
Observational
18 Years +
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2022 by AstraZeneca
AstraZeneca
Not Applicable
DISCOVER is a Non Interventional Study study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment.
DISCOVER is a NIS study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment. This study is a multi-country, multicenter, observational, prospective, longitudinal cohort study. The patients will be recruitted from countries in Latin America, Europe and Asia pac. It is estimated that approximately 13350 patients will be enrolled in total with each patient followed up for 3 years.
Location
Location
Moscow, Russian Federation
Location
Novosibirsk, Russian Federation
Location
Rostov-on-Don, Russian Federation
Location
Arkhangelsk, Russian Federation
Location
Stavropol, Russian Federation
Location
Nizhniy Novgorod, Russian Federation
Location
Saratov, Russian Federation
Location
Barnaul, Russian Federation
Arms | Assigned Interventions |
---|---|
One single cohort. One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.